Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in ...

Novo Nordisk shares plunged over 20% on Tuesday after the company named a new CEO and lowered its profit expectations, citing weaker sales of its popular weight-loss drug Wegovy due to competition ...

By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN (Reuters) -Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity drug ...

Weight-loss drugs tested in head-to-head trial Women share their bittersweet experience after taking weight-loss drugs Wegovy maker warns of slower profits as rivals bite© Getty Images ...

Patients taking the GLP-1 weight loss drug Zepbound face mandatory switch to Wegovy after CVS Caremark removed the Eli Lilly medication from its preferred coverage list, citing rising costs.

The 50-year-old is now on Novo Nordisk ’s Wegovy, but worries because it is less effective. Studies have shown Wegovy helps people lose less weight, on average, than Zepbound.

Shares in Novo Nordisk NOVO.B -0.65% plunged after it cut its guidance, a result from the company losing its lead in the booming market for weight-loss drugs, opening the door to competitors such ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long can you take semaglutide for weight loss?